Intercept Pharmaceuticals

Intercept Pharmaceuticals

Employees:
460
Market Cap:
$2.81 billion
Revenue:
$24.98 million
5 Year Trend:
69.0%
Net Income:
$-403.68 million
NASDAQ:
ICPT

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. The companys lead product is Obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747. Wikipedia

Intercept Pharmaceuticals

Employees:
460
Market Cap:
$2.81 billion
Revenue:
$24.98 million
5 Year Trend:
69.0%
Net Income:
$-403.68 million
NASDAQ:
ICPT

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. The companys lead product is Obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747. Wikipedia